Sun Pharma gets USFDA nod for generic drug Mesalamine extended release capsules

The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement. As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news